Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Description

This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.

Conditions

Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma

Study Overview

Study Details

Study overview

This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.

PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Condition
Stage IV Non-small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

Birmingham VAHCS, Birmingham, Alabama, United States, 35233

Jacksonville

Mayo Clinic, Jacksonville, Florida, United States, 32224

Miami

University of Miami, Miami, Florida, United States, 33136

Orlando

Florida Cancer Specialist and Research Institute, Orlando, Florida, United States, 32827

Orlando

Protean Biodiagnosics, Orlando, Florida, United States, 32827

Rolling Meadows

Northwest Community Healthcare, Rolling Meadows, Illinois, United States, 60008

Cedar Rapids

Helen Nassif Community Cancer Center, Cedar Rapids, Iowa, United States, 52403

New Brunswick

Rutgers Cancer Institute, New Brunswick, New Jersey, United States, 08903

Buffalo

Roswell Park, Buffalo, New York, United States, 14263

Germantown

West Clinic, Germantown, Tennessee, United States, 38138

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Cancer patients with stage IV NSCLC or stage IV malignant melanoma
  • * Patient must have at least one measurable lesion and the relevant images in order to enable assessment of response
  • * ECOG PS - 0/1-2
  • * Normal hematologic, renal and liver function:
  • 1. Absolute neutrophil count higher than 1500/mm3
  • 2. Platelets count higher than 100,000/mm3
  • 3. haemoglobin higher than 9 g/dL
  • 4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min
  • 5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit.
  • * Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug
  • * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

OncoHost Ltd.,

Alona Zer, MD, PRINCIPAL_INVESTIGATOR, 003 Rambam Medical Center

Michal Lotem, MD, PRINCIPAL_INVESTIGATOR, 001 Hadassah Medical Center

Jair Bar, MD, PRINCIPAL_INVESTIGATOR, 016 Sheba Medical Center

Maya Gottfried, MD, PRINCIPAL_INVESTIGATOR, 005 Meir Medical Center

Abed Agbaria, MD, PRINCIPAL_INVESTIGATOR, 004 Bnai Zion Medical Center

Ido Wolf, MD, PRINCIPAL_INVESTIGATOR, 002 Tel Aviv Sourasky Medical Center

Mahmud Abu-Amana, MD, PRINCIPAL_INVESTIGATOR, 007 Haemek Medical Center

Rivka Katsenelson, MD, PRINCIPAL_INVESTIGATOR, 008 Kaplan Medical Center

Alexander Yakobson, MD, PRINCIPAL_INVESTIGATOR, 009 Soroka Medical Center

Tatiana Harkovsky, MD, PRINCIPAL_INVESTIGATOR, 011 Barzilai Medical Center

Mor Moskovitz, MD, PRINCIPAL_INVESTIGATOR, 012 Rabin Medical Center

Elizabeta Dudnik, MD, PRINCIPAL_INVESTIGATOR, 013 Assuta Medical Center

Raya Leibowitz, MD, PRINCIPAL_INVESTIGATOR, 014 Shamir Medical Center

Adam Berger, MD, PRINCIPAL_INVESTIGATOR, 030 Rutgers Cancer Institute

Jose Lutzky, MD, PRINCIPAL_INVESTIGATOR, 032 University of Miami

Antony Magliocco, MD, PRINCIPAL_INVESTIGATOR, 015 Protean Biodiagnostics

Gillian Price, MD, PRINCIPAL_INVESTIGATOR, 020 Aberdeen Royal Infirmary

Helen Cheley, PRINCIPAL_INVESTIGATOR, 021 Swansea Bay UHB - Cancer Institute

Louise Medley, MD, PRINCIPAL_INVESTIGATOR, 022 Torbay and South Devon NHS foundation

Tom Geldart, MD, PRINCIPAL_INVESTIGATOR, 023 Royal Bournemouth General Hospital Dorset

Anirban Chatterjee, MD, PRINCIPAL_INVESTIGATOR, 024 The Shrewsbury and Telford Hospital

David Farrugia, MD, PRINCIPAL_INVESTIGATOR, 025 Cheltenham General Hospital

Andreas Polychronis, MD, PRINCIPAL_INVESTIGATOR, 026 Mount Vernon Cancer Centre

Andreas Polychronis, MD, PRINCIPAL_INVESTIGATOR, 027 Lister Hospital

Ari VanderWalde, MD, PRINCIPAL_INVESTIGATOR, 031 West Clinic

Davika Das, MD, PRINCIPAL_INVESTIGATOR, 033 VAHCS Birmingham

Alison Brewster, MD, PRINCIPAL_INVESTIGATOR, 051 Withybush Hospital Hawl Dda University Health Board

Adam Hassani, PRINCIPAL_INVESTIGATOR, 029 Sunderland Royal Hospital

Adam Hassani, MD, PRINCIPAL_INVESTIGATOR, 028 South Tyneside District

Andrew Conn, MD, PRINCIPAL_INVESTIGATOR, 050 Bradford Teaching Hospitals

Yanyan Lou, MD, PRINCIPAL_INVESTIGATOR, 034 Mayo Clinic

Igor Puzanov, MD, PRINCIPAL_INVESTIGATOR, 035 Roswell Park

Ernesto Bustinza, MD, PRINCIPAL_INVESTIGATOR, 153 Florida Cancer Specialists and Research Institute

Anita Sabichi, MD, PRINCIPAL_INVESTIGATOR, 036 Michael E Debakey VA Medical Center

Ronnie Shapira Frommer, MD, PRINCIPAL_INVESTIGATOR, 017 Sheba Medical Center

Ina Koch, PhD, PRINCIPAL_INVESTIGATOR, 040 Asklepios Klinik Gauting GmbH

Petros Christopoulos, MD, PRINCIPAL_INVESTIGATOR, 041 Thoraxklinik-Heidelberg gGmbH

Marina Messinger, MD, PRINCIPAL_INVESTIGATOR, 150 Northwest Community Healthcare

Sunil Patel, MD, PRINCIPAL_INVESTIGATOR, 151 CHRISTUS St. Michael Health System

William P Fusselman, MD, PRINCIPAL_INVESTIGATOR, 152 Physicians Clinic of Iowa

David Vecente, MD, PRINCIPAL_INVESTIGATOR, 044 Hospital Universitario Virgen Macarena

Study Record Dates

2029-10-01